| 000 | 01898 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250513193627.0 | ||
| 264 | 0 | _c20000113 | |
| 008 | 200001s 0 0 eng d | ||
| 022 | _a0264-410X | ||
| 024 | 7 |
_a10.1016/s0264-410x(99)00221-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKeitel, W A | |
| 245 | 0 | 0 |
_aPhase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. _h[electronic resource] |
| 260 |
_bVaccine _cOct 1999 |
||
| 300 |
_a531-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Protozoan _xblood |
| 650 | 0 | 4 | _aEpitopes, T-Lymphocyte |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLymphocyte Activation |
| 650 | 0 | 4 |
_aMalaria Vaccines _xadverse effects |
| 650 | 0 | 4 |
_aMerozoite Surface Protein 1 _ximmunology |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeptide Fragments _ximmunology |
| 650 | 0 | 4 |
_aPlasmodium falciparum _ximmunology |
| 650 | 0 | 4 | _aSkin Tests |
| 650 | 0 | 4 |
_aT-Lymphocytes, Helper-Inducer _ximmunology |
| 650 | 0 | 4 |
_aTetanus Toxoid _ximmunology |
| 650 | 0 | 4 |
_aVaccines, Synthetic _ximmunology |
| 700 | 1 | _aKester, K E | |
| 700 | 1 | _aAtmar, R L | |
| 700 | 1 | _aWhite, A C | |
| 700 | 1 | _aBond, N H | |
| 700 | 1 | _aHolland, C A | |
| 700 | 1 | _aKrzych, U | |
| 700 | 1 | _aPalmer, D R | |
| 700 | 1 | _aEgan, A | |
| 700 | 1 | _aDiggs, C | |
| 700 | 1 | _aBallou, W R | |
| 700 | 1 | _aHall, B F | |
| 700 | 1 | _aKaslow, D | |
| 773 | 0 |
_tVaccine _gvol. 18 _gno. 5-6 _gp. 531-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0264-410x(99)00221-2 _zAvailable from publisher's website |
| 999 |
_c10476963 _d10476963 |
||